The U.S. Food and Drug Administration (FDA) has just confirmed a virtual FDA listening session, co-hosted by the United Mitochondrial Disease Foundation and MitoAction, focused on Pyruvate Dehydrogenase Complex Deficiency (PDCD). The session, The Voice of the Pyruvate Dehydrogenase Complex Deficiency (PDCD) Patient Community, will be held virtually on Friday, September 8, 2023 from 1:00pm to 2:30pm ET. 

FDA listening sessions are “small, informal, non-regulatory, non-public teleconference meetings that allow participants to connect with FDA staff first-hand” to help the agency better understand specific diseases and shape things clinical trial designs, regulatory thinking, and more. FDA Listening Sessions are closed and by invitation only.

More Details Coming Soon.